Back to search
FDAFDA · Food and drugs·Recall number D-1235-2020

Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 13107-031-34

Published April 22, 2020 · Recall initiated: March 18, 2020

Summary

FDA records drug Class II recall D-1235-2020, published April 22, 2020 and initiated March 18, 2020. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 56208 units; Lot: Lot #: 031180028A, Exp. Date 03/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

What to do

Voluntary: Firm initiated · Letter

Get an email if MIRTAZAPINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
MIRTAZAPINE
Manufacturer
Aurobindo Pharma USA Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 031180028A, Exp. Date 03/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 13107-031-34 recalled?

Yes. FDA published recall D-1235-2020 on April 22, 2020. Reported hazard: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: MIRTAZAPINE.